Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q3 FY2024 Earnings Presentation
20 slides from Zim Laboratories's earnings presentation, Jan 29, 2024
Slide 1: Cover letter to BSE and NSE: Q3 & 9MFY24 Earnings Presentation
Ref No.: ZLL/CS/BSE/NSE Date: 29.01.2024 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Innovation and Differentiation for Patient-Centric Solutions: Q3 & 9MFY24 Earnings Presentation
INNOVATION AND DIFFERENTIATION FOR PATIENT-CENTRIC SOLUTIONS Q3 & 9MFY24 – EARNINGS PRESENTATION
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: ZIM Labs at a Glance
ZIM LABS AT A GLANCE o Novel Drug Delivery System Using Proprietary Manufacturing Processes o ZIM develops and supplies unique combination generic products utilizing innovative drug Rs. 2,495 Mn delivery solutions using various in-house technology platforms 9MFY24 Revenue o Sustainable R&D Spend o F
Slide 5: Highlights: Q3FY24 & 9MFY24 – Business
HIGHLIGHTS : Q3FY24 & 9MFY24 Business Highlights Business Update o FF Exports Business growing in line with strategic initiatives ; 26 % QoQ growth contributing Rs. 246 Mn for Q3FY24 o Nutra business has picked up; orders worth Rs. 180 Mn received in Q3FY24 o Contribution from high margin Government
Slide 6: Highlights: Q3FY24 & 9MFY24 – Financial
HIGHLIGHTS : Q3FY24 & 9MFY24 Financial Highlights Improved Run Rates in Total Operating Income o Our Total Operating Income grew by 12.2%, reaching Rs. 963 Mn in Q3FY24, up from Rs. 858 Mn in Q2FY24 o EBITDA margins were at 13.1% improving 60 bps QoQ o Profit After Tax grew in absolute terms from Rs
Slide 7: Growing Our Business in Target Markets
Growing Our Business in Target Markets India Revenue (Rs. Mn) Asia (Ex India) Revenue (Rs. Mn) Europe Revenue (Rs. Mn) 41 796 594 611 448 22 33% 30% 86% 9MFY23 9MFY24 9MFY23 9MFY24 9MFY23 9MFY24 Steadily moving towards making presence in stable markets o Europe: For Q3FY24 Revenue in the EU market i
Slide 8: Growth Trajectory
GROWTH TRAJECTORY Total Operating Income (Rs. Mn) EBITDA (Rs. Mn) & EBITDA Margin 1,050 1,054 1,010 15.6% 15.3% 15.3% 994 963 14.3% 14.1% 13.8% 927 13.1% 13.1% 12.5% 867 858 10.1% 775 8.8% 674 164 161 155 642 137 131 126 111 114 107 65 59 Q1FY22 Q2 Q3 Q4 Q1FY23 Q2 Q3 Q4 Q1FY24 Q2 Q3 Q1FY22 Q2 Q3 Q4
Slide 9: Business Mix
BUSINESS MIX Total Pharma Revenue (Rs. Mn) & as % of Total Operating Income Total Nutra Revenue (Rs. Mn) & as % of Total Operating Income 95% 93% 33% 89% 86% 86% 80% 77% 77% 75% 74% 26% 25% 67% 23% 23% 20% 940 14% 310 14% 807 805 11% 764 761 740 249 255 708 245 664 230 613 617 540 7% 5% 134 111 114
Slide 10: Continued Contribution from NIP and OTF
CONTINUED CONTRIBUTION FROM NIP AND OTF NIP Revenue (Rs. Mn) (NIP + OTF) Revenue (Rs. Mn) 261 168 135 72 90% 109 64 164% 82 47 49 70 9MFY23 9MFY24 Q1FY24 Q2FY24 Q3FY24 9MFY23 9MFY24 Q1FY24 Q2FY24 Q3FY24 OTF Revenue (Rs. Mn) 93 o In line with the company strategy, NIP and OTF sale contribution to Tot
Slide 11: Geographical Mix: Asia Growing
GEOGRAPHICAL MIX : ASIA GROWING Business Mix (Rs. Mn) Region wise Business Mix (%) Q2FY24 Q3FY24 33, 3% 55, 6% 48% 246, 26% 125, 15% 33% 684, 71% 31% 678, 79% 29% 29% 24% 21% 21% Exports India Deemed Exports Exports India Deemed Exports 13% 13% 13% 10% Q3FY23 7% 5% 3% 54, 5% 75, 8% Q3FY23 Q2FY24 Q3F
Slide 12: Committed to Core Strategy
COMMITED TO CORE STRATEGY Current Business: 9MFY24 Outlook Pharmaceuticals Nutraceuticals Pharmaceuticals; New Innovative Products Nutraceuticals Generic Products Generic Products Branded Generics / OTF 10 4 2 PFI FF/OTF PFI/FF FF New Products NIP Dossiers NIP Filings (Various Stages of filed planne
Slide 13: R&D at Core
R&D AT CORE R&D Initiatives R&D Expense Mix % of Total R&D Spend & Total R&D Spend as % of Total Operating Income ( ) • R&D expenses in the quarter contributed towards dossier 2% upgradation of 5 products and expansion of NIP pipeline 3% 33% 45% • Non – infringing development and manufacturing proce
Slide 14: Income Statement
INCOME STATEMENT Particulars (Rs. Mn) Q3FY24 Q2FY24 Change % (QoQ) 9MFY24 9MFY23 Change % (YoY) Total Operating Income 963 858 12.2% 2,495 2,931 (14.9%) Other Income 11 14 (21.4%) 36 57 (36.8%) Total Income 974 872 11.7% 2,531 2,988 (15.3%) EBITDA 126 107 17.8% 292 423 (31.0%) EBITDA % 13.1% 12.5% 6
Slide 15: Financial Performance - 9M & Q3FY24
FINANCIAL PERFORMANCE - 9M & Q3FY24 TotalTotal Operating Income Operating Income(Rs (Rs.Mn) Mn) EBITDA (Rs. Mn) & EBITDA % PAT (Rs. Mn) & PAT % 8.8% 12.5% 13.1% 0.3% 4.8% 5% 963 858 126 48 107 41 674 59 2 Q1FY24 Q2FY24 Q3FY24 Q1FY24 Q2FY24 Q3FY24 Q1FY24 Q2FY24 Q3FY24 14.4% 11.7% 5.9% 3.6% 2,931 172
Slide 16: Corporate
CORPORATE eal & Inova i Meine
Slide 17: Shareholding
SHAREHOLDING Ownership % (On Dec 23) Traded Volume (In K) BSE+NSE 22, 129 18, 400 41% 15, 690 17% 6, 112 5, 194 4% 3, 365 4, 250 1, 662 5% 343 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Volume(Shares) 33% o The company saw a significant increase in the number of shareholders; Q1F
Slide 18: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index ZIM (NSE) vs Nifty Healthcare Index 10,350 9,865 9, 622 31,549 9, 608 9,487 30,375 128 123 117 115 115 8, 550 106 111 113 8, 317 128 123 90 8, 009 117 115 115 87 111 113 79 79 79 28, 194 27,272 106 26, 789 23, 681 90 91 87 79 79 79 22, 182 3
Slide 19: Earnings Call Details
Q2FY24 EARNINGS CALL DETAILS Date 31st January, 2024 Time 12 Noon IST Dial – In Details Universal Access Numbers +91-22-62801557/ +91-22-71158383 Diamond Pass Click Here 18
Slide 20: Thank You
Visit ZIM Laboratories Limited: https://www.zimlab.in/ For further information, please get in touch with: ZIM’s Investor Relations Mr. Zain Daud zain.daud@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@